Figure 3.
Serum biomarkers in patients treated with JCAR014 with and without durvalumab. AUC0-28/D0 after CAR T-cell infusion of serum IFN-γ (A), macrophage inflammatory protein-1β (MIP-1β) (B), and sPD-L1 (C) according to the treatment group. (D) Serum sPD-L1 peak concentration after CAR T-cell infusion according to treatment group. (E) Serum sPD-L1 in the JCAR014 in combination with durvalumab (groups 1 and 2; NCT02706405) and JCAR014 alone cohorts (NCT01865617). (F) Serum sPD-L1 and CAR T-cell counts in the blood by qPCR in the JCAR014 in combination with durvalumab (groups 1 and 2; NCT02706405) and JCAR014 alone cohorts (NCT01865617). (E-F) Each thin line represents a single patient, and each dot represents a sample; bold lines represent the averaged data using LOESS curve fitting approximation. Mann-Whitney tests were used to compare differences between groups.

Serum biomarkers in patients treated with JCAR014 with and without durvalumab. AUC0-28/D0 after CAR T-cell infusion of serum IFN-γ (A), macrophage inflammatory protein-1β (MIP-1β) (B), and sPD-L1 (C) according to the treatment group. (D) Serum sPD-L1 peak concentration after CAR T-cell infusion according to treatment group. (E) Serum sPD-L1 in the JCAR014 in combination with durvalumab (groups 1 and 2; NCT02706405) and JCAR014 alone cohorts (NCT01865617). (F) Serum sPD-L1 and CAR T-cell counts in the blood by qPCR in the JCAR014 in combination with durvalumab (groups 1 and 2; NCT02706405) and JCAR014 alone cohorts (NCT01865617). (E-F) Each thin line represents a single patient, and each dot represents a sample; bold lines represent the averaged data using LOESS curve fitting approximation. Mann-Whitney tests were used to compare differences between groups.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal